Limits...
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.

Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, Desenclos JC, Lortholary O - Emerging Infect. Dis. (2009)

Bottom Line: We compared our data with those from the French Mycosis Study Group, a recently established voluntary network of French mycologists coordinated by the National Reference Center for Mycoses and Antifungals.The role of previous exposure to antifungal drugs lacking activity against zygomycetes could explain this increase but does not appear exclusive.We conclude that observed trends reflect a genuine increase of zygomycosis cases in at-risk populations.

View Article: PubMed Central - PubMed

Affiliation: Infectious Diseases Department, Institut de Veille Sanitaire, Saint Maurice, France. d.bitar@invs.sante.fr

ABSTRACT
We analyzed hospital records to provide a population-based estimate of zygomycosis incidence and trends over a 10-year period at a national level in France. Data showed an increasing incidence from 0.7/million in 1997 to 1.2/million in 2006 (p<0.001). We compared our data with those from the French Mycosis Study Group, a recently established voluntary network of French mycologists coordinated by the National Reference Center for Mycoses and Antifungals. We documented that incidence of zygomycosis increased, particularly in patients with hematologic malignancies or bone marrow transplants. The role of previous exposure to antifungal drugs lacking activity against zygomycetes could explain this increase but does not appear exclusive. Incidence also increased in the population of patients with diabetes mellitus. We conclude that observed trends reflect a genuine increase of zygomycosis cases in at-risk populations.

Show MeSH

Related in: MedlinePlus

Evolution of the incidence of zygomycosis, France, 1997–2006. BMT, bone marrow transplantation.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2819884&req=5

Figure 1: Evolution of the incidence of zygomycosis, France, 1997–2006. BMT, bone marrow transplantation.

Mentions: Of 828 hospital stays linked to zygomycosis, 531 incident cases were identified in public and private hospitals of metropolitan France from 1997 through 2006 There were 283 males and 248 females (sex ratio 1.1); mean age was 57.1 years (median 60 years, range: <1 month–96 years). The annual incidence rate (AIR) increased from 0.7 cases/million persons in 1997 to 1.2/million persons in 2006 (Figure 1); yearly increase was +7.4% (p<0.001). Averaged over the 10 years of study, the AIR was 0.9/million persons (95% CI 0.8–1.0). This average AIR increased with age from 0.3/million in children aged 0–9 years to 3.9/million in patients >89 years of age (Figure 2).


Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.

Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, Desenclos JC, Lortholary O - Emerging Infect. Dis. (2009)

Evolution of the incidence of zygomycosis, France, 1997–2006. BMT, bone marrow transplantation.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2819884&req=5

Figure 1: Evolution of the incidence of zygomycosis, France, 1997–2006. BMT, bone marrow transplantation.
Mentions: Of 828 hospital stays linked to zygomycosis, 531 incident cases were identified in public and private hospitals of metropolitan France from 1997 through 2006 There were 283 males and 248 females (sex ratio 1.1); mean age was 57.1 years (median 60 years, range: <1 month–96 years). The annual incidence rate (AIR) increased from 0.7 cases/million persons in 1997 to 1.2/million persons in 2006 (Figure 1); yearly increase was +7.4% (p<0.001). Averaged over the 10 years of study, the AIR was 0.9/million persons (95% CI 0.8–1.0). This average AIR increased with age from 0.3/million in children aged 0–9 years to 3.9/million in patients >89 years of age (Figure 2).

Bottom Line: We compared our data with those from the French Mycosis Study Group, a recently established voluntary network of French mycologists coordinated by the National Reference Center for Mycoses and Antifungals.The role of previous exposure to antifungal drugs lacking activity against zygomycetes could explain this increase but does not appear exclusive.We conclude that observed trends reflect a genuine increase of zygomycosis cases in at-risk populations.

View Article: PubMed Central - PubMed

Affiliation: Infectious Diseases Department, Institut de Veille Sanitaire, Saint Maurice, France. d.bitar@invs.sante.fr

ABSTRACT
We analyzed hospital records to provide a population-based estimate of zygomycosis incidence and trends over a 10-year period at a national level in France. Data showed an increasing incidence from 0.7/million in 1997 to 1.2/million in 2006 (p<0.001). We compared our data with those from the French Mycosis Study Group, a recently established voluntary network of French mycologists coordinated by the National Reference Center for Mycoses and Antifungals. We documented that incidence of zygomycosis increased, particularly in patients with hematologic malignancies or bone marrow transplants. The role of previous exposure to antifungal drugs lacking activity against zygomycetes could explain this increase but does not appear exclusive. Incidence also increased in the population of patients with diabetes mellitus. We conclude that observed trends reflect a genuine increase of zygomycosis cases in at-risk populations.

Show MeSH
Related in: MedlinePlus